Sakkarn Sangkhamanon

Dr. Sakkarn Sangkhamanon

Khon Kaen University, Thailand
+1

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Tumor Biology
Verified
Journal Article
Open access
SYSupak Yothaisong
Supak Yothaisong
HDHasaya Dokduang
Hasaya Dokduang
N*Naohiko Anzai *
Naohiko Anzai *
KHKeitaro Hayashi
Keitaro Hayashi
NNNisana Namwat
Nisana Namwat
WLWatcharin Loilome
Watcharin Loilome
Unlike normal cells, cancer cells undergo unlimited growth and multiplication, causing them to require massive amounts of amino acid to support their continuous metabolism. Among the amino acid transporters expressed on the plasma membrane, l-type amino acid transporter-1, a Na+-independent neutral amino acid transporter, is highly expressed in many types of human cancer including cholangiocarcinoma. Our previous study reported that l-type amino acid transporter-1 and its co-functional protein CD98 were highly expressed and implicated in cholangiocarcinoma progression and carcinogenesis. Therefore, this study determined the effect of JPH203, a selective inhibitor of l-type amino acid transporter-1 activity, on cholangiocarcinoma cell inhibition both in vitro and in vivo. JPH203 dramatically suppressed [14C]l-leucine uptake as well as cell growth in cholangiocarcinoma cell lines along with altering the expression of l-type amino acid transporter-1 and CD98 in response to amino acid depletion. We also demonstrated that JPH203 induced both G2/M and G0/G1 cell cycle arrest, as well as reduced the S phase accompanied by altered expression of the proteins in cell cycle progression: cyclin D1, CDK4, and CDK6. There was also cell cycle arrest of the related proteins, P21 and P27, in KKU-055 and KKU-213 cholangiocarcinoma cells. Apoptosis induction, detected by an increase in trypan blue–stained cells along with a cleaved caspase-3/caspase-3 ratio, occurred in JPH203-treated cholangiocarcinoma cells at the highest concentration tested (100 µM). As expected, daily intravenous administration of JPH203 (12.5 and 25 mg/kg) significantly inhibited tumor growth in KKU-213 cholangiocarcinoma cell xenografts in the nude mice model in a dose-dependent manner with no statistically significant change in the animal’s body weight and with no differences in the histology and appearance of the internal organs compared with the control group. Our study demonstrates that suppression of l-type amino acid transporter-1 activity using JPH203 might be used as a new therapeutic strategy for cholangiocarcinoma treatment.

28 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
STSuyanee Thongchot
Suyanee Thongchot
CVChiara Vidoni
Chiara Vidoni
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
WLWatcharin Loilome
Watcharin Loilome
NKNarong Khuntikeo
Narong Khuntikeo
Nisana NamwatNisana Namwat
Nisana Namwat
Background: Interleukin-6 (IL-6) released by cancer-associated fibroblasts (CAFs) has been shown to associate with the malignant behavior of cholangiocarcinoma (CCA). Here, we aimed to validate with clinical and molecular data the hypothesis that CAF infiltration and release of IL-6 predict poor prognosis in CCA patients following dysregulation of autophagy in cancer cells. Methods: Stromal IL-6 and cancer-cell-associated autophagy proteins LC3 and p62 were assayed by Tissue MicroArray immunohistochemistry and their expression correlated with overall survival (OS) in a cohort of 70 CCA patients. The 5-FU cytotoxicity and autophagy were determined in CCA cells cultured with CAF-conditioned medium. Results: We show that patients bearing a CCA with low production of stromal IL-6 and active autophagy flux in the cancer cells have the best prognosis and this correlates with a more effective response to post-operative chemotherapy. A similar trend was observed in CCA patients from the TCGA database. In vitro genetic manipulation of IL-6 production by primary CAFs isolated from human CCA showed that IL-6 impairs the autophagy-associated apoptotic response to 5-FU in human CCA cells. Stromal IL-6 inhibition of autophagy in cancer cells was confirmed in an animal model of CCA. Conclusion: Our data support a therapeutic strategy that includes autophagy-enhancing drugs along with adjuvants limiting the stromal inflammation (i.e., the secretion of IL-6) to improve the survival of CCA patients.

1 March 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
UTUbonrat Thamrongwaranggoon
Ubonrat Thamrongwaranggoon
WSwunchana seubwai
wunchana seubwai
CPChatchai Phoomak
Chatchai Phoomak
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
UCUbon Cha'ON
Ubon Cha'ON
SWSopit Wongkham
Sopit Wongkham

21 January 2016 in Oncology Reports
Verified
Journal Article
Closed access
HDHasaya Dokduang
Hasaya Dokduang
PYPuangrat Yongvanit
Puangrat Yongvanit
NNNisana Namwat
Nisana Namwat
CPChawalit Pairojkul
Chawalit Pairojkul
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
WLWatcharin Loilome
Watcharin Loilome
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

1 November 2018 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
KTKiril Trpkov
Kiril Trpkov
SSSakkarn Sangkhamanon
Sakkarn Sangkhamanon
AYAsli Yilmaz
Asli Yilmaz
SMShaun A.C. Medlicott
Shaun A.C. Medlicott
BDBryan Donnelly
Bryan Donnelly
MSMelissa Shea-Budgell
Melissa Shea-Budgell
The practice of assigning “case level” biopsy Grade Group (GG) or Gleason Score is variable. To our knowledge, a comparison of the concordance of different biopsy “case level” GG with the prostatectomy GG has not been done in a post-2005 prostate cancer cohort. We evaluated the GG in 2527 patients who had biopsy and radical prostatectomy performed at our institution between 2005 and 2014. We compared the agreements, the upgrades, and the downgrades of 3 different “case level” biopsy GG, with the final GG: (1) Global GG (sum of most prevalent and highest Gleason grade in any biopsy part/site-specific specimen); (2) Highest GG (found in any biopsy part/site-specific specimen); and (3) Largest Volume Cancer GG (found in any biopsy part/site-specific specimen). The concordance between the biopsy and the final GG were evaluated using weighted kappa (κ) coefficient. The biopsy Global GG, Highest GG, and Largest Volume Cancer GG were the same as the final GG in 60.4%, 57.1%, and 54.3% cases, respectively (weighted κ values: 0.49, 0.48, and 0.44, respectively). When final GG contained tertiary 5, the overall GG agreement decreased: Global GG 41.5%, Highest GG 40.3%, and Largest Volume Cancer GG 37.1% (weighted κ: 0.22, 0.21, and 0.18, respectively). A subset analysis for cases in which the biopsy Global GG and Highest GG were different (n=180) showed an agreement of 62.4% (weighted κ: 0.37) and 18.8% (weighted κ: 0.16), respectively. In patients without a tertiary Gleason pattern on radical prostatectomy, the Global GG and the Highest GG were identical in 92.4% of biopsies. Assigning a biopsy “case level” Global GG versus using the Highest GG and the Largest Volume Cancer GG resulted in comparable and slightly improved agreement with the final GG in this cohort.

26 August 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
DTDoungdean Tummanatsakun
Doungdean Tummanatsakun
TPTanakorn Proungvitaya
Tanakorn Proungvitaya
SRSittiruk Roytrakul
Sittiruk Roytrakul
TLTemduang Limpaiboon
Temduang Limpaiboon
SWSopit Wongkham
Sopit Wongkham
SPsiriporn proungvitaya
siriporn proungvitaya
Diagnostic and/or prognostic biomarkers for cholangiocarcinoma (CCA) are still insufficient with poor prognosis of patients. To discover a new CCA biomarker, we constructed our secretome database of three CCA cell lines and one control cholangiocyte cell line using GeLC-MS/MS. We selected candidate proteins by five bioinformatics tools for secretome analysis. The inclusion criteria were as follows: having predicted signal peptide or being predicted as non-classically secreted protein; together with having no transmembrane helix and being previously detected in plasma and having the highest number of signal peptide cleavage sites. Eventually, apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) was selected for further analysis. To validate APEX1 as a bio-marker for CCA, serum APEX1 levels of 80, 39, and 40 samples collected from CCA, benign biliary diseases (BBD), and healthy control groups, respectively, were measured using dot blot analysis. The results showed that serum APEX1 level in CCA group was significantly higher than that in BBD or healthy control group. Among CCA patients, serum APEX1 level was significantly higher in patients having metastasis than in those without metastasis. The higher level of serum APEX1 was correlated with the shorter survival time of the patients. Serum APEX1 level might be a diagnostic and prognostic biomarker for CCA.